Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med LifeLTS:0RO5 70 EV-to-EBIT is 98.94 as of Aug. 06, 2026, which is 196% above its 10-year median of 33.40. GuruFocus rates LTS:0RO5 with a GF Score™ of 70/100 and a GF Value™ of lei1.41 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 470 Healthcare Providers & Services companies, Med Life ranks worse than 92.34% on this metric.
The historical rank and industry rank for Med Life's EV-to-EBIT or its related term are showing as below:
LTS:0RO5'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.25 Med: 33.4 Max: 101.51
Current: 99.07
During the past 11 years, the highest EV-to-EBIT of Med Life was 101.51. The lowest was 14.25. And the median was 33.40.
LTS:0RO5's EV-to-EBIT is ranked worse than 92.34% of 470
companies
in the Healthcare Providers & Services industry
Industry Median: 15.985
vs LTS:0RO5: 99.07
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Med Life's Enterprise Value for the quarter that ended in Mar. 2026 was lei6,160 Mil.
Med Life's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life EV-to-EBIT Related Terms
Med Life EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Med Life's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Med Life's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Med Life's EV-to-EBIT falls into.
Med Life's current Enterprise Value is lei8,199 Mil.
Med Life's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (LTS:0RO5) has a EV-to-EBIT of 98.94 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Med Life and its competitors. This is 196% above median its historical median of 33.40. Over the past decade, Med Life's EV-to-EBIT has ranged from 14.25 to 101.51. According to the industry distribution chart, Med Life ranks #434 out of 470 companies in the Healthcare Providers & Services industry, placing it in the top 92.3%.
Is Med Life's EV-to-EBIT too high?
Med Life's current EV-to-EBIT of 98.94 is 196% above median its 10-year median of 33.40. Over the past 10 years, this metric has ranged from a low of 14.25 to a high of 101.51. The Healthcare Providers & Services industry median EV-to-EBIT is 15.99. Med Life's value of 98.94 is 519% above this industry median. Based on the distribution chart, Med Life ranks #434 out of 470 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Med Life has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #434 out of 470 companies for EV-to-EBIT. This places Med Life in the lower half of its industry. The industry median EV-to-EBIT is 15.99. Med Life's value of 98.94 is 519% above this benchmark. Historically, Med Life's own EV-to-EBIT has ranged from 14.25 to 101.51 over the past decade. While the company's 10-year median is 33.40 vs. the industry median of 15.99, Med Life has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.99, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current EV-to-EBIT of 98.94 is 519% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current EV-to-EBIT is 98.94, which is 196% above median its own 10-year median of 33.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.41, compared to a current price of lei11.38 — trading 706.8% above its estimated fair value. The current EV-to-EBIT is 98.94, which is 196% above median its 10-year median of 33.40 and 519% above the Healthcare Providers & Services industry median of 15.99. Med Life's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current EV-to-EBIT is 98.94 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 706.8% above its estimated GF Value™ of lei1.41.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
EV-to-EBIT: 98.94 (196% above median its 10-year median of 33.40)
GF Value™: lei1.41 vs. price of lei11.38 (706.8% above fair value)
Industry Position: 519% above the Healthcare Providers & Services median (#434 of 470)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
70GF Score
Get the complete analysis for LTS:0RO5
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
